Company Overview

Rubius Therapeutics developed our proprietary RED PLATFORM® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics™ (RCTs). Our RED PLATFORM harnesses both the unique properties of red blood cells and the creative potential of genetic engineering to deliver on the promise of cellular therapy and transform how diseases are treated.

Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create highly selective, potent and allogeneic cellular medicines aimed at treating a range of diseases. They can potentially be used to kill tumors in cancer and regulate the immune system for the treatment of autoimmune diseases.

Rubius Therapeutics is enrolling patients in a Phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors and in a second Phase 1 arm in relapsed/refractory acute myeloid leukemia. Rubius is also enrolling patients in a Phase 1 clinical trial of RTX-321 for the treatment of human papillomavirus 16-positive cancers. Additionally, Rubius plans to file an IND for RTX-224 for the treatment of solid tumors by year-end 2021.